Gillian C Goobie1, Sasha Bernatsky, Rosalind Ramsey-Goldman, Ann E Clarke. 1. aDepartment of Medicine, Cumming School of Medicine, Health Sciences Centre, Foothills Campus, University of Calgary, Calgary, Alberta bDepartment of Medicine and of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada cDivision of Rheumatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA dDivision of Rheumatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Abstract
PURPOSE OF REVIEW: Patients with systemic lupus erythematosus (SLE) have altered incidences of certain malignancies as compared with the general population. This review summarizes the recent literature on risk of malignancy in SLE and proposed mechanisms for these altered susceptibilities. RECENT FINDINGS: Recent studies have confirmed previous data showing an increased risk of non-Hodgkin's lymphoma, lung, liver, vulvar/vaginal, and thyroid malignancies, whereas demonstrating a decreased risk of breast and prostate cancer. Lymphomagenesis in SLE has been linked to increased activity of multiple inflammatory cytokines as well as possible viral diseases. The decreased rates of hormone-sensitive cancers, such as breast and prostate, are speculated to be related to the presence of lupus autoantibodies and downregulation of certain proteins in SLE. This knowledge has been utilized to investigate new therapeutic modalities for these malignancies. SUMMARY: Recent data confirm previously reported altered malignancy rates in SLE. Most striking in recent years are publications further elucidating mechanisms underlying cancer development in SLE, and subsequent investigations of potential therapeutics modulating these pathways.
PURPOSE OF REVIEW: Patients with systemic lupus erythematosus (SLE) have altered incidences of certain malignancies as compared with the general population. This review summarizes the recent literature on risk of malignancy in SLE and proposed mechanisms for these altered susceptibilities. RECENT FINDINGS: Recent studies have confirmed previous data showing an increased risk of non-Hodgkin's lymphoma, lung, liver, vulvar/vaginal, and thyroid malignancies, whereas demonstrating a decreased risk of breast and prostate cancer. Lymphomagenesis in SLE has been linked to increased activity of multiple inflammatory cytokines as well as possible viral diseases. The decreased rates of hormone-sensitive cancers, such as breast and prostate, are speculated to be related to the presence of lupus autoantibodies and downregulation of certain proteins in SLE. This knowledge has been utilized to investigate new therapeutic modalities for these malignancies. SUMMARY: Recent data confirm previously reported altered malignancy rates in SLE. Most striking in recent years are publications further elucidating mechanisms underlying cancer development in SLE, and subsequent investigations of potential therapeutics modulating these pathways.
Authors: Marco Guadagnoli; Fiona C Kimberley; Uyen Phan; Katherine Cameron; Paul M Vink; Hans Rodermond; Eric Eldering; Arnon P Kater; Hans van Eenennaam; Jan Paul Medema Journal: Blood Date: 2011-05-04 Impact factor: 22.113
Authors: James E Hansen; Grace Chan; Yanfeng Liu; Denise C Hegan; Shibani Dalal; Eloise Dray; Youngho Kwon; Yuanyuan Xu; Xiaohua Xu; Elizabeth Peterson-Roth; Erik Geiger; Yilun Liu; Joseph Gera; Joann B Sweasy; Patrick Sung; Sara Rockwell; Robert N Nishimura; Richard H Weisbart; Peter M Glazer Journal: Sci Transl Med Date: 2012-10-24 Impact factor: 17.956
Authors: Philip W Noble; Sasha Bernatsky; Ann E Clarke; David A Isenberg; Rosalind Ramsey-Goldman; James E Hansen Journal: Nat Rev Rheumatol Date: 2016-03-24 Impact factor: 20.543
Authors: Angélica M Delgado-Vega; Manuel Martínez-Bueno; Nina Y Oparina; David López Herráez; Helga Kristjansdottir; Kristján Steinsson; Sergey V Kozyrev; Marta E Alarcón-Riquelme Journal: Sci Rep Date: 2018-06-08 Impact factor: 4.379